BioCentury
ARTICLE | Financial News

True North raises $45M series D

October 18, 2016 7:00 AM UTC

Rare disease play True North Therapeutics Inc. (South San Francisco, Calif.) raised $45 million in a series D round led by new investors HBM Healthcare Investments and Redmile Group and existing investor Perceptive Advisors. New investor Franklin Templeton Investments and undisclosed existing investors also participated.

The company's TNT009, a humanized mAb against complement component 1 s subcomponent (C1S), is in Phase Ib testing to treat complement-mediated diseases including cold agglutinin disease (CAD), bullous pemphigoid, warm autoimmune hemolytic anemia and end-stage renal disease (ESRD) (see BioCentury, April 21, 2014). ...